Related Experiment Video
Updated: Sep 21, 2025

Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be
Tabea Schlemeyer1, Denise Ohnezeit1, Sanamjeet Virdi2
1Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract:
Merkel cell polyomavirus is the causative agent for most Merkel cell carcinomas (MCCs). This highly aggressive skin cancer shows rapid progression, with metastasis being a significant challenge for patient therapy. Virus-positive MCCs show low mutation rates, and tumor cell proliferation is dependent on viral oncoproteins small T antigen (sT) and large T antigen. Although the role of sT and large T antigen in early events of tumorigenesis has been extensively studied, their role in tumor progression has been scarcely addressed. In this study, we investigate the possible mechanisms of how Merkel cell polyomavirus oncoproteins, particularly sTs, contribute to metastasis. We show that sT specifically affects selectin ligand binding and processing by altering the presentation of multiple MCC surface molecules, thereby influencing initial metastasis events and tumor cell immune recognition. Furthermore, we show that sT regulates the surface antigen CD47, which inhibits phagocytosis by macrophages. By applying either sT short hairpin RNAs, CD47-targeted small interfering RNAs, or a therapeutic anti-CD47 antibody, we show that immune recognition of MCC cells can be restored. Thus, CD47 is a promising therapeutic target on MCC cells. Blocking the CD47‒SIRPα interaction effectively promotes phagocytosis of MCC cells and might be a promising combinatorial immunotherapy approach together with PD-1/PD-L1 axis in MCC treatment.
Insights
Merkel cell polyomavirus small T antigen (sT) drives Merkel cell carcinoma (MCC) metastasis by altering cell surface molecules and CD47 expression. Restoring immune recognition via CD47 blockade offers a potential MCC immunotherapy strategy.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Merkel cell carcinoma (MCC) is an aggressive skin cancer linked to Merkel cell polyomavirus.
- Viral oncoproteins, particularly small T antigen (sT), are crucial for MCC development, but their role in metastasis is less understood.
Purpose of the Study:
- To investigate how Merkel cell polyomavirus oncoproteins, specifically sT, contribute to MCC metastasis.
- To identify potential therapeutic targets for MCC treatment.
Main Methods:
- Investigated sT's effect on MCC surface molecule presentation and selectin ligand binding.
- Analyzed sT's regulation of CD47, an inhibitor of phagocytosis.
- Utilized sT short hairpin RNAs, CD47-targeted small interfering RNAs, and anti-CD47 antibodies in MCC cell models.
Main Results:
- sT alters MCC surface molecule presentation, impacting metastasis and immune recognition.
- sT upregulates CD47 on MCC cells, inhibiting macrophage phagocytosis.
- Restoring immune recognition and promoting phagocytosis was achieved by targeting sT or CD47.
Conclusions:
- CD47 is a promising therapeutic target in MCC, as blocking its interaction with SIRPα enhances phagocytosis.
- Targeting the CD47–SIRPα axis may be a viable combinatorial immunotherapy for MCC, potentially alongside PD-1/PD-L1 inhibitors.
Related Concept Videos
Tumor Immunotherapy
Mitogens and the Cell Cycle
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation

